Theravance Biopharma Inc. Revenue 2012–2025
Theravance Biopharma Inc. annual/quarterly revenue history and growth rate from 2012 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Theravance Biopharma Inc. revenue for the quarter ending March 31, 2026 was 17.7 M, a 15.02% increase year-over-year.
- Theravance Biopharma Inc. revenue for the twelve months ending March 31, 2026 was 79.3 M, a 29.28% increase year-over-year.
- Theravance Biopharma Inc. annual revenue for 2025 was 107.5 M, a 66.92% increase from 2024.
- Theravance Biopharma Inc. annual revenue for 2024 was 64.4 M, a 12.12% increase from 2023.
- Theravance Biopharma Inc. annual revenue for 2023 was 57.4 M, a 11.84% increase from 2022.
- Theravance Biopharma Inc. annual revenue for 2022 was 51.3 M.
Theravance Biopharma Inc. (TBPH) — Frequently Asked Questions
Theravance Biopharma Inc. (TBPH) is a publicly traded US company. It has a market capitalization of $843M. In fiscal 2025 it reported revenue of $107M and net income of $106M. Explore TBPH's stock price, financial statements, earnings history, margins and key ratios below.
What is Theravance Biopharma Inc.'s market cap?
Theravance Biopharma Inc. (TBPH) has a market capitalization of $843M.
What is the TBPH stock price?
TBPH trades at $16.37 (-0.73% on the day).
How much revenue does Theravance Biopharma Inc. make?
Theravance Biopharma Inc. reported revenue of $107M in fiscal 2025.
Is TBPH profitable?
In fiscal 2025, Theravance Biopharma Inc. reported net income of $106M.
What is TBPH's P/E ratio?
Based on diluted EPS, TBPH has a price-to-earnings (P/E) ratio of about 7.9.